Last updated: February 17, 2025
Sponsor: Eisai Co., Ltd.
Overall Status: Active - Recruiting
Phase
N/A
Condition
Alzheimer's Disease
Memory Loss
Dementia
Treatment
No Intervention
Clinical Study ID
NCT06322667
BAN2401-J081-401
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- All participants who are treated with lecanemab in routine clinical practice
Exclusion
Exclusion Criteria:
- None
Study Design
Total Participants: 5000
Treatment Group(s): 1
Primary Treatment: No Intervention
Phase:
Study Start date:
February 14, 2024
Estimated Completion Date:
December 31, 2027
Connect with a study center
Eisai trial site 2
Hiroshima,
JapanActive - Recruiting
Eisai trial site 3
Kyoto,
JapanActive - Recruiting
Eisai trial site 1
Tokyo,
JapanActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.